title: Current developments in pharmacogenomics of multiple sclerosis.
abstract: Pharmacogenomics has a significant potential to impact how we treat diseases. It involves targeting genetically identifiable populations with therapeutic interventions that promises to yield immediate positive health outcomes with lower or no side effects. The 'trial and error' method of treatment will no longer be necessary with the successful implementation of personalized medicine. The following is an overview of some new developments in pharmacogenomics of multiple sclerosis, and how it has the potential to improve future treatment.
authors.affiliation: Laboratory of Molecular Cell Biology, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, S7N 5C9, Canada.
authors.forename: Rebecca J
authors.initials: RJ
authors.lastname: Carlson
authors.forename: J Ronald
authors.initials: JR
authors.lastname: Doucette
authors.forename: Adil J
authors.initials: AJ
authors.lastname: Nazarali
mesh_terms: D000818:Animals; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000235:genetics*; D010597:Pharmacogenetics / Q000639:trends*; D012106:Research / Q000639:trends